PL1641453T3 - Produkt obejmujący co najmniej jeden inhibitor fosfatazy Cdc25 w kombinacji z co najmniej jednym innym środkiem przeciwnowotworowym - Google Patents

Produkt obejmujący co najmniej jeden inhibitor fosfatazy Cdc25 w kombinacji z co najmniej jednym innym środkiem przeciwnowotworowym

Info

Publication number
PL1641453T3
PL1641453T3 PL04767442T PL04767442T PL1641453T3 PL 1641453 T3 PL1641453 T3 PL 1641453T3 PL 04767442 T PL04767442 T PL 04767442T PL 04767442 T PL04767442 T PL 04767442T PL 1641453 T3 PL1641453 T3 PL 1641453T3
Authority
PL
Poland
Prior art keywords
product containing
anticancer agent
inhibitor combined
phosphatase cdc25
cdc25 inhibitor
Prior art date
Application number
PL04767442T
Other languages
English (en)
Polish (pl)
Inventor
Grégoire Prevost
Pannetier Marie-Christine Brezak
Original Assignee
Ipsen Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma filed Critical Ipsen Pharma
Publication of PL1641453T3 publication Critical patent/PL1641453T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL04767442T 2003-06-25 2004-06-24 Produkt obejmujący co najmniej jeden inhibitor fosfatazy Cdc25 w kombinacji z co najmniej jednym innym środkiem przeciwnowotworowym PL1641453T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0307649A FR2856688B1 (fr) 2003-06-25 2003-06-25 PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
PCT/FR2004/001586 WO2005000852A2 (fr) 2003-06-25 2004-06-24 Produit comprenant au moins un inhibiteur de phosphates cdc25 en association avec au moins un autre agent anti-cancereux
EP04767442A EP1641453B1 (fr) 2003-06-25 2004-06-24 Produit comprenant au moins un inhibiteur de phosphates cdc25 en association avec au moins un autre agent anti-cancereux

Publications (1)

Publication Number Publication Date
PL1641453T3 true PL1641453T3 (pl) 2010-01-29

Family

ID=33515382

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04767442T PL1641453T3 (pl) 2003-06-25 2004-06-24 Produkt obejmujący co najmniej jeden inhibitor fosfatazy Cdc25 w kombinacji z co najmniej jednym innym środkiem przeciwnowotworowym

Country Status (14)

Country Link
US (3) US20060281736A1 (enExample)
EP (3) EP2335702A1 (enExample)
JP (2) JP2007514639A (enExample)
AR (2) AR044930A1 (enExample)
AT (1) ATE439836T1 (enExample)
CA (1) CA2530668A1 (enExample)
DE (1) DE602004022674D1 (enExample)
DK (1) DK1641453T3 (enExample)
ES (1) ES2332137T3 (enExample)
FR (1) FR2856688B1 (enExample)
MX (1) MXPA06000216A (enExample)
MY (1) MY141725A (enExample)
PL (1) PL1641453T3 (enExample)
WO (1) WO2005000852A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0215336A (pt) * 2001-12-27 2004-11-16 Scras Utilização de um composto ou um sal farmaceuticamente aceitável do mesmo, composto, e composição farmacêutica
FR2834289B1 (fr) * 2001-12-27 2004-03-19 Sod Conseils Rech Applic Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques
FR2856688B1 (fr) * 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
DE10353792A1 (de) 2003-11-13 2005-06-23 Exner, Heinrich, Dr.med.vet. Heil- und Wundsalbe auf der Basis einer wässrigen Emulsion
FR2877667B1 (fr) * 2004-11-05 2007-03-23 Sod Conseils Rech Applic Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques
FR2879460B1 (fr) * 2004-12-17 2007-02-23 Sod Conseils Rech Applic Associations anti-douleur comprenant un derive de dihydroimidazopyrazine
FR2879598B1 (fr) * 2004-12-17 2007-03-30 Sod Conseils Rech Applic Inhibiteurs de phosphatases cdc25
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
EP2190924B1 (de) * 2007-09-06 2011-05-25 Basf Se Blends aus verzweigten polyarylethern und hydrophilen polymeren
US8389527B2 (en) 2008-02-06 2013-03-05 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
JO3156B1 (ar) 2009-07-09 2017-09-20 Novartis Ag ايميدازولات مدمجة والتركيبات التي تشملها لعلاج الأمراض الطفيلية على مثال الملاريا
BR122017028566B1 (pt) * 2010-11-12 2022-03-03 Pharma Mar, S.A. Uso de pm01183, ou um sal farmaceuticamente aceitável do mesmo, em combinação sinérgica com um antibiótico anticâncer e kit
EP3615030A1 (en) 2017-04-24 2020-03-04 Novartis AG Therapeutic regimen of 2-amino-l-(2-(4-fluorophenyl)-3-(4-fluorophenylamino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8h)-yl)ethanone and combinations thereof
WO2021067572A2 (en) * 2019-10-01 2021-04-08 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for inhibiting carp-1 binding to nemo
EP4061372A1 (en) 2019-11-21 2022-09-28 Pharma Mar, S.A. Methods of treating small cell lung cancer with lurbinectedin formulations
US11981645B1 (en) 2023-10-10 2024-05-14 King Faisal University N′-(2-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as antimicrobial compound

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US735674A (en) * 1902-01-29 1903-08-04 William C Matthias Sparking igniter for explosive-engines.
FR50000E (fr) 1938-11-29 1939-09-29 Moulin à café
US5523430A (en) * 1994-04-14 1996-06-04 Bristol-Myers Squibb Company Protein farnesyl transferase inhibitors
US6673927B2 (en) * 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
US6383871B1 (en) * 1999-08-31 2002-05-07 Micron Technology, Inc. Method of forming multiple oxide thicknesses for merged memory and logic applications
DE60016625T2 (de) * 1999-11-09 2005-12-22 Societe De Conseils De Recherches Et D'applications Scientifiques(S.C.R.A.S.) Zusammensetzung enthaltend einen inhibitor der signaltransduktion von heterotrimerischen g-proteinen in kombination mit einem anderen anti-krebs-mittel zu einer therapeutischen verwendung in der krebsbehandlung
FR2812198B1 (fr) * 2000-07-28 2008-07-18 Sod Conseils Rech Applic DERIVES D'AMIDINES INHIBITEURS DE PHOSPHATASES cdc25
WO2002050079A1 (fr) * 2000-12-20 2002-06-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
FR2825278A1 (fr) * 2001-05-30 2002-12-06 Sod Conseils Rech Applic Produit comprenant du mikanolide, du dihydromikanolide ou un analogue de ceux-ci en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
TW200304375A (en) * 2001-12-06 2003-10-01 Maxia Pharmaceuticals Inc 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer
FR2834289B1 (fr) * 2001-12-27 2004-03-19 Sod Conseils Rech Applic Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques
BR0215336A (pt) * 2001-12-27 2004-11-16 Scras Utilização de um composto ou um sal farmaceuticamente aceitável do mesmo, composto, e composição farmacêutica
FR2856686A1 (fr) * 2003-06-25 2004-12-31 Sod Conseils Rech Applic Benzothiazole-4,7-diones et benzooxazole-4,7-diones substituees en position 5 ou 6 et leurs procedes de preparation
FR2856688B1 (fr) * 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
JP4273056B2 (ja) * 2004-08-12 2009-06-03 不二越機械工業株式会社 研磨装置

Also Published As

Publication number Publication date
FR2856688B1 (fr) 2008-05-30
WO2005000852A2 (fr) 2005-01-06
ATE439836T1 (de) 2009-09-15
US20060281736A1 (en) 2006-12-14
FR2856688A1 (fr) 2004-12-31
JP2007514639A (ja) 2007-06-07
EP1641453B1 (fr) 2009-08-19
US20090253685A1 (en) 2009-10-08
MY141725A (en) 2010-06-15
ES2332137T3 (es) 2010-01-27
US20090137596A1 (en) 2009-05-28
JP2009149694A (ja) 2009-07-09
CA2530668A1 (fr) 2005-01-06
EP2335702A1 (fr) 2011-06-22
DE602004022674D1 (de) 2009-10-01
WO2005000852A3 (fr) 2005-06-30
AR044930A1 (es) 2005-10-12
AR070977A2 (es) 2010-05-19
MXPA06000216A (es) 2006-04-11
EP1641453A2 (fr) 2006-04-05
DK1641453T3 (da) 2009-12-14
EP1792905A1 (fr) 2007-06-06

Similar Documents

Publication Publication Date Title
PL1641453T3 (pl) Produkt obejmujący co najmniej jeden inhibitor fosfatazy Cdc25 w kombinacji z co najmniej jednym innym środkiem przeciwnowotworowym
IL196033A0 (en) Pyrrolotriazine derivatives and pharmaceutical compositions containing the same
IL182664A0 (en) Triazole derivatives and pharmaceutical compositions containing the same
IL188050A0 (en) Azaindazole derivatives and pharmaceutical compositions containing the same
IL183919A0 (en) Triazolophthalazine derivatives and pharmaceutical compositions containing the same
IL178174A0 (en) Polycyclic pyridine compounds and pharmaceutical compositions containing the same
IL187224A0 (en) Bicyclic derivatives and pharmaceutical compositions containing the same
IL173602A0 (en) Heteroarylaminosulfonylphenyl derivatives and pharmaceutical compositions containing the same
IL174863A0 (en) Compounds that inhibit serine proteases and pharmaceutical compositions containing the same
IL191141A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
IL186665A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
IL187434A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
IL189782A (en) The history of sulfonylpyrol and its medicinal products and their use
IL196167A0 (en) Bicyclic compounds and pharmaceutical compositions containing the same
IL190017A0 (en) Bicyclic compounds and pharmaceutical compositions containing the same
IL187997A0 (en) Indane derivatives and pharmaceutical compositions containing the same
IL171997A0 (en) Pyrrolodihydroisoquinoline derivatives and pharmaceutical compositions containing the same
IL221323A0 (en) 1-methyl-1h- pyridin-2-one- phenanthridine derivatives and pharmaceutical compositions containing the same
IL177168A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
IL179496A0 (en) Triazole derivatives and pharmaceutical compositions containing the same
IL175210A0 (en) Non-pancreatic proteases and pharmaceutical compositions containing the same
IL184996A0 (en) Dihydroimidazothiazole derivatives and pharmaceutical compositions containing the same
IL174305A0 (en) 5-arylpyrimidines as anticancer agents
IL177744A0 (en) Aptamers and pharmaceutical compositions containing the same
IL169794A0 (en) Office products containing antimicrobial agent